{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-063884","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.700744+00:00","generated_at":"2026-06-14T15:31:37.596805+00:00","sec_items":["1.01","1.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eloxx reports ELX-02 Phase 2 topline: one patient remission; opens $50M ATM offering","bullets":["One of two completed patients achieved remission (≥50% UPCR decline); five of eight readings averaged 53% below baseline.","Second patient showed no significant UPCR change; both had same Col4A4 mutation but different RAAS inhibitor levels.","ELX-02 generally well tolerated; no discontinuations; kidney biopsies showed no nephrotoxicity.","Entered ATM agreement with Oppenheimer for up to $50M common stock sales, currently limited to $6.5M due to S-3 limits.","Prior SVB Leerink ATM agreement terminated; no shares were sold under that agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-063884","json":"https://secwatch.observer/filing/0001104659-23-063884.json","markdown":"https://secwatch.observer/filing/0001104659-23-063884.md","text":"https://secwatch.observer/filing/0001104659-23-063884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/0001104659-23-063884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/tm2316480d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T15:31:37.596805+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bd267dea4b33844763449598f690a93500e0754","claim":"Eloxx Pharmaceuticals, Inc. terminated SVB Sales Agreement with SVB Leerink LLC (effective 2023-05-24).","evidence_excerpt":"nto a Sales Agreement (the “SVB Sales Agreement”) with SVB Leerink LLC (“Cowen”) to sell shares of the Company’s Common Stock with aggregate gross sales proceeds of up to $50 million, from time to time, through an “at the market” equity","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/0001104659-23-063884-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"SVB Leerink LLC"},{"label":"Effective","value":"2023-05-24"}],"fact_type":"material_agreement"},{"claim_id":"f3670af887d609d9884392f586ebad9f6607222b","claim":"Eloxx Pharmaceuticals, Inc. entered into Oppenheimer Sales Agreement with Oppenheimer & Co. Inc. valued at aggregate gross sales proceeds of up to $50.0 million (effective 2023-05-24).","evidence_excerpt":"On May 24, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Oppenheimer Sales Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”) pursuant to which the Company may offer and sell shares of its common stock, par value $0.01 per share (the “Common Stock”), having aggregate gross sales proceeds of up to $50.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/0001104659-23-063884-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Oppenheimer & Co. Inc."},{"label":"Value","value":"aggregate gross sales proceeds of up to $50.0 million"},{"label":"Effective","value":"2023-05-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}